HQH
Signal
Bullish Setup2
Price
1
Move+1.79%Positive session
Volume
1
Volume0.7× avgNormal activity
Technical
1
RSIRSI 57Momentum positive
PRICE
Prev Close
19.50
Open
19.60
Day Range19.60 – 19.85
19.60
19.85
52W Range15.09 – 20.46
15.09
20.46
89% of range
VOLUME & SIZE
Avg Volume
170.7K
FUNDAMENTALS
P/E Ratio
12.3x
Value territory
EPS (TTM)
Div Yield
0.10%
Beta
0.79
Low vol
Performance
1D
+1.79%
5D
+2.16%
1M
+15.07%
3M
+3.93%
6M
+1.48%
YTD
+4.80%
1Y
+22.23%
Best: 1Y (+22.23%)
Quick Read
TrendInsufficient MA data
Momentum
BULLISH
revenue +90% YoY · 77% gross margin
Valuation
CHEAP
P/E 12x vs ~20x sector
Health
MODERATE
CR 0.0 (low) · FCF $0.16/sh
Strong Buy
Key MetricsTTM
Market Cap$1.14B
Revenue TTM$32.46M
Net Income TTM$331.56M
Free Cash Flow$8.72M
Gross Margin77.2%
Net Margin1150.1%
Operating Margin770.3%
Return on Equity24.0%
Return on Assets23.6%
Debt / Equity0.00
Current Ratio0.04
EPS TTM$4.72

Intelligence analysis not yet available for this stock. Full AI-powered analysis may be available on the intelligence page.

Health Radar
3 strong3 concern
39/100
Liquidity
0.04Concern
Leverage
0.00Strong
Coverage
0.0xConcern
ROE
24.0%Strong
ROIC
15.8%Strong
Cash
$59Concern
Analyst Coverage

No analyst coverage available for this stock.

Stock Health
Composite Score
2 of 3 signals bullish
8/10
Technicals
RSI RangeRSI 57 — Bullish momentum
Volume
Volume FlowAccumulation — institutional buying
Fundamentals
LiquidityCurrent Ratio 0.04 — liquidity risk

2 signals unavailable — limited data for this stock

Upcoming Events
EEarnings ReportMay 2, 2026
Tomorrow
DEx-Dividend DateJul 30, 2026
In 90 days
PDividend PaymentOct 27, 2026
In 179 days
Technicals
Technical SetupBULLISH
Technicals →

Trend

UptrendGolden Cross · 50D leads 200D by 9.4%

+2.9% vs SMA 50 · +12.6% vs SMA 200

Momentum

RSI57.1
Positive momentum, not extended
MACD+0.11
Above zero — bullish momentum · compressing
Market Position
Price Levels
52W High
$20.46+3.1%
Current
$19.85
EMA 50
$19.32-2.7%
EMA 200
$17.65-11.1%
52W Low
$15.09-24.0%
52-Week RangeNear 52-week high
$15.0989th %ile$20.46
Squeeze SetupVolume-based
Elevated Squeeze Setup

Strong accumulation on above-average volume. Buyers are absorbing supply aggressively — any positive catalyst could trigger a rapid covering move.

20-Day Money Flow
Acc days:5
Dist days:2
Edge:+3 acc
Volume Context
Avg Vol (50D)231K
Recent Vol (5D)
350K+52%

Based on volume distribution analysis. Direct short interest data (short float %, days to cover) is not available in current data sources.

Earnings & Analysts
Insider Activity
SEC Filings →
6 Buys/0 SellsNet Buying
Dimartino RoseDir
$19K
Jul 16
BUY
Goetz KathleenDir
$9K
Apr 9
BUY
Goodson Alan RVice President
$3K
Dec 21
BUY
Reit ToddDir
$17K
Jan 2
BUY
Maher BillDir
$17K
Dec 28
BUY
Omstead Daniel RDir
$149K
Sep 25
BUY
Financials
Dividends11.34% yield
+3.8% avg annual growth
Annual Yield11.34%
Quarterly Div.$0.6300
Est. Annual / Share$2.52
FrequencyQuarterly
Q2'24
Q3'24
Q4'24
Q1'25
Q2'25
Q3'25
Q4'25
Q1'26

Dividend per payment — last 8 periods

INSTITUTIONAL OWNERSHIP

1
Janney Montgomery Scott LLC
205K
2
Samalin Investment Counsel, LLC
126K
3
OPPENHEIMER & CO INC
117K
4
COMMONWEALTH EQUITY SERVICES, LLC
75K
5
Sage Capital Management, LLC
62K
6
Private Advisor Group, LLC
56K
7
Cyndeo Wealth Partners, LLC
38K
8
Pensionmark Financial Group, LLC
35K
News & Activity

HQH News

20 articles · 4h ago

About

tekla life sciences investors is a closed-ended equity mutual fund launched and managed by tekla capital management llc. the fund invests in public equity markets across the globe. it seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries. the fund primarily invests in growth stocks of small cap companies. it employs fundamental analysis with a focus on factors such as market position for services or products, experience of business management, technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. the fund benchmarks the performance of its portfolio against the nasdaq biotech index and the s&p 500 index. it was form

Frank T. GentileSenior Vice President of Research and Portfolio Manager
Christopher F. BrinzeySenior Vice President of Research and Portfolio Manager
Jason C. AkusVice President of Research and Portfolio Manager
Peers(7 companies)
Screen sector →
SymbolPriceDay %Mkt CapP/ERev GrwMarginELO
HQH
$19.85+1.79%$1.1B4.2+82683.7%9879.8%1500
$396.06+0.57%$2.1T28.7+3296.8%4510.0%1500
$91.86+2.89%$318.3B14.0+318.8%1510.7%1500
$131.91+1.13%$306.2B22.6+586.3%1305.9%1500
$187.37+1.17%$290.5B28.1+862.9%1745.9%1500
$147.85+3.44%$282.1B21.0+597.3%2564.4%1500
$90.67+1.98%$256.7B14.5-591.0%668.4%1500
Sector avg+1.85%19.0+12536.4%3169.3%1500